Detalhe da pesquisa
1.
Immune Checkpoint Inhibitors in "Special" NSCLC Populations: A Viable Approach?
Int J Mol Sci
; 24(16)2023 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37628803
2.
Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer.
Int J Mol Sci
; 24(22)2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38003273
3.
Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models.
Int J Mol Sci
; 22(6)2021 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33802212
4.
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Lancet Oncol
; 20(12): 1702-1709, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31628016
5.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Lancet Oncol
; 20(10): 1395-1408, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31422028
6.
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Oncologist
; 24(11): e1165-e1171, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30996007
7.
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
Br J Cancer
; 118(1): 38-42, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29149104
8.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(2): 123-35, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26028407
9.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(17): 1627-39, 2015 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-26412456
10.
Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Tumour Biol
; 40(11): 1010428318815047, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30486741
11.
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 18(7): 874-886, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28602779
12.
Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
BMC Cancer
; 17(1): 502, 2017 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28747156
13.
Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
JAMA
; 317(18): 1844-1853, 2017 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28492898
14.
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 17(12): 1643-1652, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27751847
15.
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
N Engl J Med
; 368(25): 2385-94, 2013 Jun 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23724913
16.
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
J Neurooncol
; 129(2): 355-61, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27324494
17.
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Lancet Oncol
; 16(3): 328-37, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25701171
18.
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Int J Mol Sci
; 16(1): 747-57, 2014 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-25561229
19.
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
Lancet Oncol
; 14(1): 38-47, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23200175
20.
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients.
Cancers (Basel)
; 16(3)2024 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38339345